liposomal cytarabine + methotrexate

The combination of liposomal cytarabine and methotrexate is used primarily for intrathecal (IT) administration in the treatment of central nervous system (CNS) involvement in various cancers, particularly leptomeningeal metastasis and CNS involvement in hematologic malignancies. Liposomal cytarabine is a sustained-release formulation of cytarabine encapsulated in liposomes, which provides prolonged drug exposure in the cerebrospinal fluid (CSF). This formulation allows for less frequent administration compared to conventional cytarabine[3]. When combined with methotrexate, this regimen targets malignant cells in the CNS through different mechanisms of action. ## Efficacy and Clinical Use The combination has been studied in various clinical settings: - For leptomeningeal metastasis from solid tumors, with a median non-glioblastoma overall survival of 30.2 weeks in one retrospective study[1] - For CNS prophylaxis in acute lymphoblastic leukemia (ALL)[2] - For treatment of CNS relapse in ALL and Burkitt's lymphoma/leukemia, with complete cytological remission achieved in 74% of patients in one study[3] ## Administration and Dosing Typical administration involves: - Liposomal cytarabine: 50 mg intrathecally in adults (in children: 2 mg/kg/dose, maximum 35 mg for children under 13 years, 50 mg for older children)[5] - Methotrexate: Administered intrathecally, often with systemic therapy - Frequency: Often given every 2 weeks[3][5] - Dexamethasone: Commonly administered concurrently (orally or intrathecally) to prevent arachnoiditis[2][5] ## Safety Considerations The combination therapy has important safety considerations: - Neurotoxicity can occur, particularly when combined with systemic chemotherapy that crosses the blood-brain barrier[2] - Serious adverse events reported include seizures, papilledema, cauda equina syndrome, and encephalitis[2] - Headache is the most frequent adverse event[3] - Risk of neurotoxicity may be higher when administered concurrently with high-dose systemic methotrexate and cytarabine[2] - Premedication with dexamethasone is recommended to reduce the risk of arachnoiditis[5] When compared individually, randomized trials comparing single-agent intrathecal methotrexate to liposomal cytarabine have shown similar efficacy and tolerability[1]. The combination approach was developed to potentially improve outcomes, particularly in difficult-to-treat CNS disease. The combination therapy represents an important treatment option for CNS involvement in various malignancies, though careful monitoring for neurotoxicity is essential, particularly when used concurrently with systemic chemotherapy that penetrates the blood-brain barrier.

Brand names

DepoCyt

Other names

HD-MTX and Liposomal CytarabineIntrathecal Liposomal CytarabineHigh-Dose Methotrexate and Liposomal Cytarabine